Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 208

1.

The C-terminal extension landscape of naturally presented HLA-I ligands.

Guillaume P, Picaud S, Baumgaertner P, Montandon N, Schmidt J, Speiser DE, Coukos G, Bassani-Sternberg M, Filippakopoulos P, Gfeller D.

Proc Natl Acad Sci U S A. 2018 May 15;115(20):5083-5088. doi: 10.1073/pnas.1717277115. Epub 2018 Apr 30.

PMID:
29712860
2.

T cell-induced CSF1 promotes melanoma resistance to PD1 blockade.

Neubert NJ, Schmittnaegel M, Bordry N, Nassiri S, Wald N, Martignier C, Tillé L, Homicsko K, Damsky W, Maby-El Hajjami H, Klaman I, Danenberg E, Ioannidou K, Kandalaft L, Coukos G, Hoves S, Ries CH, Fuertes Marraco SA, Foukas PG, De Palma M, Speiser DE.

Sci Transl Med. 2018 Apr 11;10(436). pii: eaan3311. doi: 10.1126/scitranslmed.aan3311.

PMID:
29643229
3.

Simultaneous enumeration of cancer and immune cell types from bulk tumor gene expression data.

Racle J, de Jonge K, Baumgaertner P, Speiser DE, Gfeller D.

Elife. 2017 Nov 13;6. pii: e26476. doi: 10.7554/eLife.26476.

4.

T cell receptor alpha variable 12-2 bias in the immunodominant response to Yellow fever virus.

Bovay A, Zoete V, Dolton G, Bulek AM, Cole DK, Rizkallah PJ, Fuller A, Beck K, Michielin O, Speiser DE, Sewell AK, Fuertes Marraco SA.

Eur J Immunol. 2018 Feb;48(2):258-272. doi: 10.1002/eji.201747082. Epub 2017 Dec 11.

5.

More T Cells versus Better T Cells in Patients with Breast Cancer.

Speiser DE, Verdeil G.

Cancer Discov. 2017 Oct;7(10):1062-1064. doi: 10.1158/2159-8290.CD-17-0858.

PMID:
28974529
6.

Tumor lymphangiogenesis promotes T cell infiltration and potentiates immunotherapy in melanoma.

Fankhauser M, Broggi MAS, Potin L, Bordry N, Jeanbart L, Lund AW, Da Costa E, Hauert S, Rincon-Restrepo M, Tremblay C, Cabello E, Homicsko K, Michielin O, Hanahan D, Speiser DE, Swartz MA.

Sci Transl Med. 2017 Sep 13;9(407). pii: eaal4712. doi: 10.1126/scitranslmed.aal4712.

PMID:
28904226
7.

Tumor infiltrating lymphocytes in lymph node metastases of stage III melanoma correspond to response and survival in nine patients treated with ipilimumab at the time of stage IV disease.

Diem S, Hasan Ali O, Ackermann CJ, Bomze D, Koelzer VH, Jochum W, Speiser DE, Mertz KD, Flatz L.

Cancer Immunol Immunother. 2018 Jan;67(1):39-45. doi: 10.1007/s00262-017-2061-4. Epub 2017 Sep 11.

PMID:
28894934
8.

TCR-ligand dissociation rate is a robust and stable biomarker of CD8+ T cell potency.

Allard M, Couturaud B, Carretero-Iglesia L, Duong MN, Schmidt J, Monnot GC, Romero P, Speiser DE, Hebeisen M, Rufer N.

JCI Insight. 2017 Jul 20;2(14). pii: 92570. doi: 10.1172/jci.insight.92570. [Epub ahead of print]

9.

ILC2-modulated T cell-to-MDSC balance is associated with bladder cancer recurrence.

Chevalier MF, Trabanelli S, Racle J, Salomé B, Cesson V, Gharbi D, Bohner P, Domingos-Pereira S, Dartiguenave F, Fritschi AS, Speiser DE, Rentsch CA, Gfeller D, Jichlinski P, Nardelli-Haefliger D, Jandus C, Derré L.

J Clin Invest. 2017 Aug 1;127(8):2916-2929. doi: 10.1172/JCI89717. Epub 2017 Jun 26.

10.

Design of short peptides to block BTLA/HVEM interactions for promoting anticancer T-cell responses.

Spodzieja M, Lach S, Iwaszkiewicz J, Cesson V, Kalejta K, Olive D, Michielin O, Speiser DE, Zoete V, Derré L, Rodziewicz-Motowidło S.

PLoS One. 2017 Jun 8;12(6):e0179201. doi: 10.1371/journal.pone.0179201. eCollection 2017.

11.

Heterogeneity assessment of functional T cell avidity.

Ioannidou K, Baumgaertner P, Gannon PO, Speiser MF, Allard M, Hebeisen M, Rufer N, Speiser DE.

Sci Rep. 2017 Mar 13;7:44320. doi: 10.1038/srep44320.

12.

Immunoregulation of Dendritic Cell Subsets by Inhibitory Receptors in Urothelial Cancer.

Chevalier MF, Bohner P, Pieraerts C, Lhermitte B, Gourmaud J, Nobile A, Rotman S, Cesson V, Martin V, Legris AS, Dartiguenave F, Gharbi D, De Leval L, Speiser DE, Nardelli-Haefliger D, Jichlinski P, Derré L.

Eur Urol. 2017 Jun;71(6):854-857. doi: 10.1016/j.eururo.2016.10.009. Epub 2016 Oct 27.

PMID:
28277277
13.

Broad and Conserved Immune Regulation by Genetically Heterogeneous Melanoma Cells.

Neubert NJ, Tillé L, Barras D, Soneson C, Baumgaertner P, Rimoldi D, Gfeller D, Delorenzi M, Fuertes Marraco SA, Speiser DE.

Cancer Res. 2017 Apr 1;77(7):1623-1636. doi: 10.1158/0008-5472.CAN-16-2680. Epub 2017 Jan 19.

14.

T memory stem cells in health and disease.

Gattinoni L, Speiser DE, Lichterfeld M, Bonini C.

Nat Med. 2017 Jan 6;23(1):18-27. doi: 10.1038/nm.4241. Review.

PMID:
28060797
15.

Very Late Antigen-1 Marks Functional Tumor-Resident CD8 T Cells and Correlates with Survival of Melanoma Patients.

Murray T, Fuertes Marraco SA, Baumgaertner P, Bordry N, Cagnon L, Donda A, Romero P, Verdeil G, Speiser DE.

Front Immunol. 2016 Dec 12;7:573. doi: 10.3389/fimmu.2016.00573. eCollection 2016.

16.

Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer.

Hasan Ali O, Diem S, Markert E, Jochum W, Kerl K, French LE, Speiser DE, Früh M, Flatz L.

Oncoimmunology. 2016 Sep 19;5(11):e1231292. doi: 10.1080/2162402X.2016.1231292. eCollection 2016.

17.

Rapid and Continued T-Cell Differentiation into Long-term Effector and Memory Stem Cells in Vaccinated Melanoma Patients.

Gannon PO, Baumgaertner P, Huber A, Iancu EM, Cagnon L, Abed Maillard S, Maby-El Hajjami H, Speiser DE, Rufer N.

Clin Cancer Res. 2017 Jul 1;23(13):3285-3296. doi: 10.1158/1078-0432.CCR-16-1708. Epub 2016 Nov 21.

PMID:
27872103
18.

Vaccination of stage III/IV melanoma patients with long NY-ESO-1 peptide and CpG-B elicits robust CD8+ and CD4+ T-cell responses with multiple specificities including a novel DR7-restricted epitope.

Baumgaertner P, Costa Nunes C, Cachot A, Maby-El Hajjami H, Cagnon L, Braun M, Derré L, Rivals JP, Rimoldi D, Gnjatic S, Abed Maillard S, Marcos Mondéjar P, Protti MP, Romano E, Michielin O, Romero P, Speiser DE, Jandus C.

Oncoimmunology. 2016 Sep 9;5(10):e1216290. eCollection 2016.

19.

Magnetic nanoparticle-induced hyperthermia with appropriate payloads: Paul Ehrlich's "magic (nano)bullet" for cancer theranostics?

Datta NR, Krishnan S, Speiser DE, Neufeld E, Kuster N, Bodis S, Hofmann H.

Cancer Treat Rev. 2016 Nov;50:217-227. doi: 10.1016/j.ctrv.2016.09.016. Epub 2016 Oct 3. Review.

PMID:
27756009
20.

Pembrolizumab-triggered Uveitis: An Additional Surrogate Marker for Responders in Melanoma Immunotherapy?

Diem S, Keller F, Rüesch R, Maillard SA, Speiser DE, Dummer R, Siano M, Urner-Bloch U, Goldinger SM, Flatz L.

J Immunother. 2016 Nov/Dec;39(9):379-382.

21.

A Well-Controlled Experimental System to Study Interactions of Cytotoxic T Lymphocytes with Tumor Cells.

Neubert NJ, Soneson C, Barras D, Baumgaertner P, Rimoldi D, Delorenzi M, Fuertes Marraco SA, Speiser DE.

Front Immunol. 2016 Aug 30;7:326. doi: 10.3389/fimmu.2016.00326. eCollection 2016.

22.

Regulatory circuits of T cell function in cancer.

Speiser DE, Ho PC, Verdeil G.

Nat Rev Immunol. 2016 Oct;16(10):599-611. doi: 10.1038/nri.2016.80. Epub 2016 Aug 16. Review.

PMID:
27526640
23.

Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients.

Derré L, Cesson V, Lucca I, Cerantola Y, Valerio M, Fritschi U, Vlamopoulos Y, Burruni R, Legris AS, Dartiguenave F, Gharbi D, Martin V, Vaucher L, Speiser DE, Romero P, Jichlinski P, Nardelli-Haefliger D.

Clin Cancer Res. 2017 Feb 1;23(3):717-725. doi: 10.1158/1078-0432.CCR-16-1189. Epub 2016 Aug 12.

24.

Anticancer Teamwork: Cross-Presenting Dendritic Cells Collaborate with Therapeutic Monoclonal Antibodies.

Robert-Tissot C, Speiser DE.

Cancer Discov. 2016 Jan;6(1):17-9. doi: 10.1158/2159-8290.CD-15-1366.

25.

Identifying Individual T Cell Receptors of Optimal Avidity for Tumor Antigens.

Hebeisen M, Allard M, Gannon PO, Schmidt J, Speiser DE, Rufer N.

Front Immunol. 2015 Nov 18;6:582. doi: 10.3389/fimmu.2015.00582. eCollection 2015. Review.

26.

Identification of melanoma cells and lymphocyte subpopulations in lymph node metastases by FTIR imaging histopathology.

Wald N, Bordry N, Foukas PG, Speiser DE, Goormaghtigh E.

Biochim Biophys Acta. 2016 Feb;1862(2):202-12. doi: 10.1016/j.bbadis.2015.11.008. Epub 2015 Nov 21.

27.

STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity.

Demaria O, De Gassart A, Coso S, Gestermann N, Di Domizio J, Flatz L, Gaide O, Michielin O, Hwu P, Petrova TV, Martinon F, Modlin RL, Speiser DE, Gilliet M.

Proc Natl Acad Sci U S A. 2015 Dec 15;112(50):15408-13. doi: 10.1073/pnas.1512832112. Epub 2015 Nov 25.

28.

Vaccination with LAG-3Ig (IMP321) and Peptides Induces Specific CD4 and CD8 T-Cell Responses in Metastatic Melanoma Patients--Report of a Phase I/IIa Clinical Trial.

Legat A, Maby-El Hajjami H, Baumgaertner P, Cagnon L, Abed Maillard S, Geldhof C, Iancu EM, Lebon L, Guillaume P, Dojcinovic D, Michielin O, Romano E, Berthod G, Rimoldi D, Triebel F, Luescher I, Rufer N, Speiser DE.

Clin Cancer Res. 2016 Mar 15;22(6):1330-40. doi: 10.1158/1078-0432.CCR-15-1212. Epub 2015 Oct 23.

29.

Genome-wide RNA profiling of long-lasting stem cell-like memory CD8 T cells induced by Yellow Fever vaccination in humans.

Fuertes Marraco SA, Soneson C, Delorenzi M, Speiser DE.

Genom Data. 2015 Jul 2;5:297-301. doi: 10.1016/j.gdata.2015.06.024. eCollection 2015 Sep.

30.

High-throughput monitoring of human tumor-specific T-cell responses with large peptide pools.

Chevalier MF, Bobisse S, Costa-Nunes C, Cesson V, Jichlinski P, Speiser DE, Harari A, Coukos G, Romero P, Nardelli-Haefliger D, Jandus C, Derré L.

Oncoimmunology. 2015 May 27;4(10):e1029702. eCollection 2015 Oct.

31.

Inhibitory Receptors Beyond T Cell Exhaustion.

Fuertes Marraco SA, Neubert NJ, Verdeil G, Speiser DE.

Front Immunol. 2015 Jun 26;6:310. doi: 10.3389/fimmu.2015.00310. eCollection 2015. Review.

32.

Molecular profiling of CD8 T cells in autochthonous melanoma identifies Maf as driver of exhaustion.

Giordano M, Henin C, Maurizio J, Imbratta C, Bourdely P, Buferne M, Baitsch L, Vanhille L, Sieweke MH, Speiser DE, Auphan-Anezin N, Schmitt-Verhulst AM, Verdeil G.

EMBO J. 2015 Aug 4;34(15):2042-58. doi: 10.15252/embj.201490786. Epub 2015 Jul 2.

33.

Consensus nomenclature for CD8+ T cell phenotypes in cancer.

Apetoh L, Smyth MJ, Drake CG, Abastado JP, Apte RN, Ayyoub M, Blay JY, Bonneville M, Butterfield LH, Caignard A, Castelli C, Cavallo F, Celis E, Chen L, Colombo MP, Comin-Anduix B, Coukos G, Dhodapkar MV, Dranoff G, Frazer IH, Fridman WH, Gabrilovich DI, Gilboa E, Gnjatic S, Jäger D, Kalinski P, Kaufman HL, Kiessling R, Kirkwood J, Knuth A, Liblau R, Lotze MT, Lugli E, Marincola F, Melero I, Melief CJ, Mempel TR, Mittendorf EA, Odun K, Overwijk WW, Palucka AK, Parmiani G, Ribas A, Romero P, Schreiber RD, Schuler G, Srivastava PK, Tartour E, Valmori D, van der Burg SH, van der Bruggen P, van den Eynde BJ, Wang E, Zou W, Whiteside TL, Speiser DE, Pardoll DM, Restifo NP, Anderson AC.

Oncoimmunology. 2015 Feb 25;4(4):e998538. eCollection 2015 Apr.

34.

From T cell "exhaustion" to anti-cancer immunity.

Verdeil G, Fuertes Marraco SA, Murray T, Speiser DE.

Biochim Biophys Acta. 2016 Jan;1865(1):49-57. doi: 10.1016/j.bbcan.2015.06.007. Epub 2015 Jun 27. Review.

PMID:
26123831
35.

Quantitative TCR:pMHC Dissociation Rate Assessment by NTAmers Reveals Antimelanoma T Cell Repertoires Enriched for High Functional Competence.

Gannon PO, Wieckowski S, Baumgaertner P, Hebeisen M, Allard M, Speiser DE, Rufer N.

J Immunol. 2015 Jul 1;195(1):356-66. doi: 10.4049/jimmunol.1403145. Epub 2015 May 22.

36.

Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients.

Romano E, Kusio-Kobialka M, Foukas PG, Baumgaertner P, Meyer C, Ballabeni P, Michielin O, Weide B, Romero P, Speiser DE.

Proc Natl Acad Sci U S A. 2015 May 12;112(19):6140-5. doi: 10.1073/pnas.1417320112. Epub 2015 Apr 27.

37.

Long-lasting stem cell-like memory CD8+ T cells with a naïve-like profile upon yellow fever vaccination.

Fuertes Marraco SA, Soneson C, Cagnon L, Gannon PO, Allard M, Abed Maillard S, Montandon N, Rufer N, Waldvogel S, Delorenzi M, Speiser DE.

Sci Transl Med. 2015 Apr 8;7(282):282ra48. doi: 10.1126/scitranslmed.aaa3700.

PMID:
25855494
38.

Identification of Rare High-Avidity, Tumor-Reactive CD8+ T Cells by Monomeric TCR-Ligand Off-Rates Measurements on Living Cells.

Hebeisen M, Schmidt J, Guillaume P, Baumgaertner P, Speiser DE, Luescher I, Rufer N.

Cancer Res. 2015 May 15;75(10):1983-91. doi: 10.1158/0008-5472.CAN-14-3516. Epub 2015 Mar 25.

39.

Cancer immunotherapy drives implementation science in oncology.

Speiser DE, Flatz L.

Hum Vaccin Immunother. 2014;10(11):3107-10. doi: 10.4161/21645515.2014.983000.

40.

An infrared spectral signature of human lymphocyte subpopulations from peripheral blood.

Wald N, Legat A, Meyer C, Speiser DE, Goormaghtigh E.

Analyst. 2015 Apr 7;140(7):2257-65. doi: 10.1039/c4an02247e.

PMID:
25553786
41.

Classification of current anticancer immunotherapies.

Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buqué A, Senovilla L, Baracco EE, Bloy N, Castoldi F, Abastado JP, Agostinis P, Apte RN, Aranda F, Ayyoub M, Beckhove P, Blay JY, Bracci L, Caignard A, Castelli C, Cavallo F, Celis E, Cerundolo V, Clayton A, Colombo MP, Coussens L, Dhodapkar MV, Eggermont AM, Fearon DT, Fridman WH, Fučíková J, Gabrilovich DI, Galon J, Garg A, Ghiringhelli F, Giaccone G, Gilboa E, Gnjatic S, Hoos A, Hosmalin A, Jäger D, Kalinski P, Kärre K, Kepp O, Kiessling R, Kirkwood JM, Klein E, Knuth A, Lewis CE, Liblau R, Lotze MT, Lugli E, Mach JP, Mattei F, Mavilio D, Melero I, Melief CJ, Mittendorf EA, Moretta L, Odunsi A, Okada H, Palucka AK, Peter ME, Pienta KJ, Porgador A, Prendergast GC, Rabinovich GA, Restifo NP, Rizvi N, Sautès-Fridman C, Schreiber H, Seliger B, Shiku H, Silva-Santos B, Smyth MJ, Speiser DE, Spisek R, Srivastava PK, Talmadge JE, Tartour E, Van Der Burg SH, Van Den Eynde BJ, Vile R, Wagner H, Weber JS, Whiteside TL, Wolchok JD, Zitvogel L, Zou W, Kroemer G.

Oncotarget. 2014 Dec 30;5(24):12472-508. Review.

42.

Pulmonary sarcoid-like granulomatosis after multiple vaccinations of a long-term surviving patient with metastatic melanoma.

Bordry N, Costa-Nunes CM, Cagnon L, Gannon PO, Abed-Maillard S, Baumgaertner P, Murray T, Letovanec I, Lazor R, Bouchaab H, Rufer N, Romano E, Michielin O, Speiser DE.

Cancer Immunol Res. 2014 Dec;2(12):1148-53. doi: 10.1158/2326-6066.CIR-14-0143. Epub 2014 Oct 2.

43.

T cell differentiation in chronic infection and cancer: functional adaptation or exhaustion?

Speiser DE, Utzschneider DT, Oberle SG, Münz C, Romero P, Zehn D.

Nat Rev Immunol. 2014 Nov;14(11):768-74. doi: 10.1038/nri3740. Epub 2014 Sep 26. Review.

44.

Deciphering the unusual HLA-A2/Melan-A/MART-1-specific TCR repertoire in humans.

Romero P, Speiser DE, Rufer N.

Eur J Immunol. 2014 Sep;44(9):2567-70. doi: 10.1002/eji.201445004.

45.

Microtubule-depolymerizing agents used in antibody-drug conjugates induce antitumor immunity by stimulation of dendritic cells.

Müller P, Martin K, Theurich S, Schreiner J, Savic S, Terszowski G, Lardinois D, Heinzelmann-Schwarz VA, Schlaak M, Kvasnicka HM, Spagnoli G, Dirnhofer S, Speiser DE, von Bergwelt-Baildon M, Zippelius A.

Cancer Immunol Res. 2014 Aug;2(8):741-55. doi: 10.1158/2326-6066.CIR-13-0198. Epub 2014 Apr 21.

46.

MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a Phase I trial.

Romano E, Michielin O, Voelter V, Laurent J, Bichat H, Stravodimou A, Romero P, Speiser DE, Triebel F, Leyvraz S, Harari A.

J Transl Med. 2014 Apr 12;12:97. doi: 10.1186/1479-5876-12-97.

47.

Development of a T cell receptor targeting an HLA-A*0201 restricted epitope from the cancer-testis antigen SSX2 for adoptive immunotherapy of cancer.

Abate-Daga D, Speiser DE, Chinnasamy N, Zheng Z, Xu H, Feldman SA, Rosenberg SA, Morgan RA.

PLoS One. 2014 Mar 28;9(3):e93321. doi: 10.1371/journal.pone.0093321. eCollection 2014.

48.

IRF4 and BATF are critical for CD8⁺ T-cell function following infection with LCMV.

Grusdat M, McIlwain DR, Xu HC, Pozdeev VI, Knievel J, Crome SQ, Robert-Tissot C, Dress RJ, Pandyra AA, Speiser DE, Lang E, Maney SK, Elford AR, Hamilton SR, Scheu S, Pfeffer K, Bode J, Mittrücker HW, Lohoff M, Huber M, Häussinger D, Ohashi PS, Mak TW, Lang KS, Lang PA.

Cell Death Differ. 2014 Jul;21(7):1050-60. doi: 10.1038/cdd.2014.19. Epub 2014 Feb 14.

49.

Inhibitory Receptor Expression Depends More Dominantly on Differentiation and Activation than "Exhaustion" of Human CD8 T Cells.

Legat A, Speiser DE, Pircher H, Zehn D, Fuertes Marraco SA.

Front Immunol. 2013 Dec 19;4:455. doi: 10.3389/fimmu.2013.00455. eCollection 2013.

50.

Radioimmunotherapy combined with maintenance anti-CD20 antibody may trigger long-term protective T cell immunity in follicular lymphoma patients.

Buchegger F, Larson SM, Mach JP, Chalandon Y, Dietrich PY, Cairoli A, Prior JO, Romero P, Speiser DE.

Clin Dev Immunol. 2013;2013:875343. doi: 10.1155/2013/875343. Epub 2013 Nov 26. Review.

Supplemental Content

Loading ...
Support Center